Pipitone RM, Ciccioli C, Infantino G et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145548. https://doi.org/10.1177/20420188221145549.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Sun M, Cao Y et al. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload. Arch Biochem Biophys. 2020;695:108642. https://doi.org/10.1016/j.abb.2020.108642.

Article  CAS  PubMed  Google Scholar 

Mantovani A, Morieri ML, Palmisano L et al. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus. Cardiovasc Diabetol. 2023;22:204. https://doi.org/10.1186/s12933-023-01945-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Liu Q, Pan Y et al. New insights into the role of dietary triglyceride absorption in obesity and metabolic diseases. Front Pharmacol. 2023;14:1097835. https://doi.org/10.3389/fphar.2023.1097835.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nan Y, An J, Bao J et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75:454–461. https://doi.org/10.1016/j.jhep.2021.05.003.

Article  CAS  PubMed  Google Scholar 

Tourkochristou E, Mouzaki A, Triantos C. Gene polymorphisms and biological effects of vitamin D receptor on nonalcoholic fatty liver disease development and progression. Int J Mol Sci. 2023;24:8288. https://doi.org/10.3390/ijms24098288.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heyens LJM, Busschots D, Koek GH et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med. 2021;8:615978. https://doi.org/10.3389/fmed.2021.615978.

Article  Google Scholar 

Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–2224. https://doi.org/10.1016/S0140-6736(20)32511-3.

Article  CAS  PubMed  Google Scholar 

Fang Z, Liu C, Cheng Y et al. Combined analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics reveals the expression patterns of lipid metabolism and ferroptosis in the immune microenvironment of metabolic-associated fatty liver disease. Life Sci. 2025;362:123377. https://doi.org/10.1016/j.lfs.2025.123377.

Article  CAS  PubMed  Google Scholar 

Torres J-L, Novo-Veleiro I, Manzanedo L et al. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol. 2018;24:4104–4118. https://doi.org/10.3748/wjg.v24.i36.4104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kozumi K, Kodama T, Murai H et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74:2452–2466. https://doi.org/10.1002/hep.31995.

Article  CAS  PubMed  Google Scholar 

Govaere O, Cockell S, Tiniakos D et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. 2020;12:eaba4448. https://doi.org/10.1126/scitranslmed.aba4448.

Article  CAS  PubMed  Google Scholar 

Pirola CJ, Sookoian S. Metabolic dysfunction-associated fatty liver disease: Advances in genetic and epigenetic implications. Curr Opin Lipidol. 2022;33:95–102. https://doi.org/10.1097/MOL.0000000000000814.

Article  CAS  PubMed  Google Scholar 

Selvaraj EA, Mózes FE, Jayaswal ANA et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021;75:770–785. https://doi.org/10.1016/j.jhep.2021.04.044.

Article  PubMed  Google Scholar 

Huang Z, Xia X, Liang Y et al. Assessment and integration of multiparametric MRI for liver fibrosis staging in rat non-alcoholic steatohepatitis: Evaluation of diagnostic efficiency and model interpretation. Eur J Radiol. 2025;182:111821. https://doi.org/10.1016/j.ejrad.2024.111821.

Article  PubMed  Google Scholar 

Chen D-B, Xie X-W, Zhao Y-J et al. RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A. Sci Rep. 2020;10:14538. https://doi.org/10.1038/s41598-020-71403-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Wang X, Shen Q et al. DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2. Cell Oncol (Dordr). 2022;45:1187–1202. https://doi.org/10.1007/s13402-022-00709-1.

Article  CAS  PubMed  Google Scholar 

Wang J, Chen Y, Xu Y et al. DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma. Theranostics. 2024;14:6798–6817. https://doi.org/10.7150/thno.102995.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Fang Y, Li D et al. Constructing a prognostic model for hepatocellular carcinoma based on bioinformatics analysis of inflammation-related genes. Front Med (Lausanne). 2024;11:1420353. https://doi.org/10.3389/fmed.2024.1420353.

Article  PubMed  PubMed Central  Google Scholar 

Zhou J, Pang J, Tripathi M et al. Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nat Commun. 2022;13:5202. https://doi.org/10.1038/s41467-022-32788-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newberry EP, Hall Z, Xie Y et al. Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer. Hepatology (Baltimore, Md). 2021;74:1203–1219. https://doi.org/10.1002/hep.31771.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schilter H, Findlay AD, Perryman L et al. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis. J Cell Mol Med. 2019;23:1759–1770. https://doi.org/10.1111/jcmm.14074.

Article  CAS  PubMed  Google Scholar 

Gwag T, Reddy Mooli RG, Li D et al. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease. JHEP Rep. 2021;3:100193. https://doi.org/10.1016/j.jhepr.2020.100193.

Article  PubMed  Google Scholar 

Troelstra MA, Witjes JJ, van Dijk A-M et al. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: the amsterdam NAFLD-NASH cohort. J Magn Reson Imaging. 2021;54:1937–1949. https://doi.org/10.1002/jmri.27703.

Article  PubMed  PubMed Central  Google Scholar 

Idilman IS, Celik A, Savas B et al. The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study. Clin Radiol. 2021;76:709.e13-709.e18. https://doi.org/10.1016/j.crad.2021.06.014.

Article  CAS  PubMed  Google Scholar 

Takayama Y, Nishie A, Ishimatsu K et al. Diagnostic potential of T1ρ and T2 relaxations in assessing the severity of liver fibrosis and necro-inflammation. Magn Reson Imaging. 2022;87:104–112. https://doi.org/10.1016/j.mri.2022.01.002.

Article  CAS  PubMed  Google Scholar 

Luetkens JA, Klein S, Träber F et al. Quantification of liver fibrosis at T1 and T2 mapping with extracellular volume fraction MRI: preclinical results. Radiology. 2018;288:748–754. https://doi.org/10.1148/radiol.2018180051.

Article  PubMed  Google Scholar